September 17, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: | AzurRx BioPharma, Inc. | |
Registration Statement on Form S-3 (File No. 333-240129) | ||
Filed on July 27, 2020 |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, AzurRx BioPharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 9:00 a.m., Eastern Standard Time, on September 21, 2020, or as soon as practicable thereafter.
Please call James O’Grady of Lowenstein Sandler LLP at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours, | |||||
AZURRX BIOPHARMA, INC. | |||||
By: /s/ James Sapirstein | |||||
Name: James Sapirstein | |||||
Title: President and Chief Executive Officer |
|